ADHD Prevalence: What Population Research Actually Measures
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention and/or hyperactivity-impulsivity that interfere with functioning or development. Its population prevalence is estimated through epidemiological research, but any quoted percentage is meaningful only alongside the age group, location, diagnostic definition, data source, ascertainment procedure, and year to which it applies. Epidemiology therefore asks several connected questions: how many people meet clinical criteria, how many have been recognized by a clinician, how many have ever received a diagnosis, and how these quantities change across the lifespan and between groups. The answers are related, but they are different statistical quantities. World Federation of ADHD consensus statement; NICE guideline NG87.
A global umbrella review published in 2023 estimated ADHD prevalence among children and adolescents at 8.0% (95% confidence interval 6.0%–10.0%), pooling information across 13 systematic reviews involving 588 primary studies and more than 3.2 million participants. This is a synthesis of heterogeneous studies rather than a contemporary census of clinically diagnosed children. Earlier analyses have produced estimates closer to 5%–6%, while the 2024 U.S. National Survey of Children's Health reported that 11.7% of children ages 3–17 currently had a parent-reported ADHD diagnosis. Each result answers a different question under different sampling, clinical, and reporting conditions. Ayano et al., 2023; Polanczyk et al., 2014; HRSA, 2026.
For adults, a global meta-analysis estimated 2.58% for persistent adult ADHD with evidence of childhood onset and 6.76% for symptomatic adult ADHD using broader symptom-based definitions, after demographic adjustment to the world population in 2020. A U.S. survey conducted in late 2023 separately estimated that 6.0% of adults reported a current ADHD diagnosis. These figures cannot be substituted for one another: diagnostic history, symptom criteria, childhood-onset requirements, and sampling frames alter the numerator and the denominator. Song et al., 2021; CDC MMWR, 2024.
The essential distinction: prevalence, incidence, diagnosis, and service demand
Prevalence is the proportion of a defined population meeting a specified case definition during a specified period. Point prevalence refers to a particular point in time; period prevalence covers a defined interval; lifetime or ever-diagnosed prevalence records whether someone met a condition or received a diagnosis at any earlier point. Incidence concerns new cases or newly recorded diagnoses within a period. In ADHD administrative data, first-recorded diagnosis may reflect first clinical recognition of a longstanding condition rather than biological onset. Referrals, waiting lists, medication prescriptions, and internet searches measure service activity or public attention, not population prevalence.
The diagnostic status of ADHD matters. Epidemiologic surveys using a structured interview and evidence of symptoms, onset, duration, impairment, and more than one setting are closer to a clinical case definition than surveys counting only high scores on a screening scale. Parent report that a clinician has diagnosed ADHD is an important surveillance measure of recognition and access, but it does not independently re-evaluate diagnostic criteria. A primary-care billing code counts a contact recorded in a health system, and a prescription database captures treated people within its coverage. None of those indicators is a universal substitute for a carefully conducted population assessment. NICE NG87; Martin et al., 2025.
Worldwide Childhood and Adolescent ADHD Prevalence
International syntheses establish that ADHD occurs across continents, languages, economic circumstances, and health systems. A comprehensive 2014 meta-regression of studies across three decades found that methodological characteristics accounted for a substantial part of the apparent variation between estimates. The choice of diagnostic criteria, information sources, age composition, and impairment requirements can shift a reported rate even when the underlying population risk has not changed. It found no compelling secular increase attributable simply to calendar time in the studies analyzed. The World Federation of ADHD subsequently summarized meta-analytic evidence supporting prevalence near 5.9% among youth under a particular synthesis, underscoring that estimates should be attached to the methods producing them. Polanczyk et al., 2014; Faraone et al., 2021.
An umbrella review by Ayano and colleagues published in 2023 pooled 13 previous systematic-review meta-analyses and arrived at 8.0% among children and adolescents, with a 95% confidence interval spanning 6.0% to 10.0%. The pooled estimate is informative about the breadth of the literature. Because umbrella reviews may encompass overlapping primary studies and heterogeneous diagnostic methods, the total number of included participants should not be interpreted as an independently sampled worldwide denominator. The interval reflects statistical uncertainty in the chosen synthesis; variation between settings and measures adds further interpretive uncertainty. Ayano et al., 2023.
A separate 2023 systematic review and meta-analysis by Salari and colleagues emphasized age differences, including varying estimates for school-age children and adolescents. Rates can differ between younger children, whose behavior is often evaluated relative to developmental expectations, and adolescents, whose motor activity and social settings change. The study also reinforces the need to distinguish studies requiring full diagnostic criteria from those reporting elevated symptoms. Salari et al., 2023.
Why there is no single context-free global percentage
A worldwide prevalence figure combines studies performed in different years using different definitions. Sampling may exclude children outside formal schooling, people in unstable housing, children with language barriers, or adolescents no longer enrolled in school. Some studies depend entirely on parent or teacher checklists; others obtain structured diagnostic interviews. Some require impairment in multiple environments; others apply a symptom threshold. A pooled proportion averages those conditions with statistical weights and assumptions. It is more useful to cite a defensible range and its methods than to treat the second decimal place as a permanent characteristic of human populations.
Prevalence in specialist or clinical samples is expected to exceed prevalence in general-population samples because people entering those services have already been selected for difficulties or co-occurring conditions. A 2025 meta-analysis of ADHD or hyperkinetic disorder in clinical populations reported pooled estimates of 32.4% among pediatric clinical samples and 21.4% among adult clinical samples. These are within-clinic proportions; they do not imply that one third of all children or one fifth of all adults have ADHD. Referral patterns, service specialties, and comorbidity determine the populations represented. Clinical-settings meta-analysis, 2025.
ADHD Prevalence in the United States
The 2024 National Survey of Children's Health
The most directly comparable recent U.S. surveillance measure is parent-reported current ADHD diagnosis in the National Survey of Children's Health. A Health Resources and Services Administration data brief released in July 2026 reported that 11.7% of U.S. children ages 3–17 had a current ADHD diagnosis in data collected in 2024, representing about 7.1 million children. The study estimated 14.5% among boys and 8.8% among girls. Its population and outcome are explicitly children ages 3–17 with a diagnosis reported as current, not all children meeting an independently administered clinical assessment or all adults with symptoms. HRSA, 2026; 2024 survey query.
Age-stratified 2024 diagnosed prevalence among boys was 3.7% at ages 3–5, 16.2% at ages 6–11, and 17.5% at ages 12–17. Among girls, the corresponding values were 1.6%, 8.7%, and 12.0%. These gradients summarize the accumulation of recognition and differences in developmental expression, exposure to academic demands, and opportunities for assessment. They should not be read as an individual-level risk curve proving ADHD biologically begins during adolescence. ADHD is defined as a neurodevelopmental condition with childhood manifestations; clinical diagnosis may occur much later. HRSA, 2026.
The difference between the published 2024 survey estimate of approximately 7.1 million and CDC's rounded presentation of approximately 7 million illustrates ordinary rounding, not conflicting findings. The denominator is a weighted estimate of the child population represented by the survey; raw respondent counts are not population counts. Survey weights attempt to improve national representativeness, but self-report, nonresponse, and changing coverage can remain sources of error. The associated survey data resource supplies confidence intervals and unweighted samples alongside population estimates. NSCH Data Resource Center, 2024.
Why 2022 figures seem to disagree with 2024 figures
A peer-reviewed analysis of the 2022 National Survey of Children's Health found that 11.4% of U.S. children ages 3–17 had ever been diagnosed with ADHD, while 10.5% had a current diagnosis. The corresponding estimated counts were about 7.1 million ever diagnosed and 6.5 million currently diagnosed. These are two different outcomes collected in the same survey year. Comparing the 2022 ever-diagnosed percentage with 2024 current-diagnosis prevalence and treating them as one continuous series introduces a definition error. A rigorous trend analysis holds the question wording, age range, survey design, and diagnostic definition as constant as possible. Bitsko et al., 2024.
A history of diagnosis can remain in the ever-diagnosed category after a parent no longer describes the child as currently having ADHD. A current-diagnosis category excludes some people whose diagnosis is reported as historical. Differences can also arise from changes in survey composition or response behavior. When comparing 2022 and 2024, the appropriate current-versus-current comparison is 10.5% in 2022 versus 11.7% in 2024, accompanied by the data collection details and uncertainty rather than an unsupported claim of a sudden underlying biological increase. Bitsko et al., 2024; HRSA, 2026.
Adult ADHD in U.S. surveillance
The CDC's Morbidity and Mortality Weekly Report analysis used National Center for Health Statistics Rapid Surveys System data collected in October–November 2023. It estimated that 6.0% of U.S. adults, about 15.5 million people, had a current ADHD diagnosis based on self-report. Its estimated 95% confidence interval for the percentage was 5.3%–6.8%. Among adults reporting current ADHD, 55.9% said they were diagnosed at age 18 or older. Adult age at diagnosis is a measure of when recognition occurred; it cannot establish that symptoms first developed at that age. CDC MMWR, 2024.
The same survey reported substantial variability in treatment and service use among adults with ADHD. Approximately 36.5% of those with a current diagnosis reported receiving neither medication nor counseling or behavioral treatment in the period assessed. Estimates of untreated or undertreated need cannot be calculated from diagnosis prevalence alone: some people have ongoing impairments while others may have remitted symptoms, obtained environmental support, or chosen alternative strategies. Population statistics identify important service questions but do not determine what care an individual needs. CDC MMWR, 2024.
Adult ADHD Worldwide: Two Distinct Definitions
The global adult meta-analysis by Song and colleagues separated persistent adult ADHD, which requires childhood onset, from symptomatic adult ADHD, defined by current symptoms whether or not childhood onset had been established. After standardization to the 2020 global population structure, it estimated 2.58% persistent ADHD (95% confidence interval 1.51%–4.45%) and 6.76% symptomatic adult ADHD (95% confidence interval 4.31%–10.61%). These are distinct operational definitions. The broader symptom estimate should not be presented as the prevalence of clinically confirmed adult ADHD without recognizing that adult symptoms may also occur with other conditions and that diagnostic history can be difficult to ascertain. Song et al., 2021.
The estimates changed with age: persistent adult ADHD was estimated at 5.05% among ages 18–24 and 0.77% among adults 60 and older, while symptomatic estimates were 8.99% and 4.51% in those same age strata. Cross-sectional age gradients combine developmental symptom changes, retrospective recall difficulties, cohort effects, selective survival, and measurement properties. They do not demonstrate that every person with ADHD improves by an equivalent percentage with age. Song et al., 2021.
Persistence, remission, and ascertainment in later life
The meaning of persistence depends on whether researchers require a full current symptom count, substantial impairment, continuation of medication, or evidence of a childhood-to-adulthood symptom trajectory. A person may fall below a strict symptom threshold while still experiencing significant executive-function or occupational problems. Conversely, temporary attention difficulties caused by inadequate sleep, anxiety, depression, medical illness, or other factors should not be counted automatically as lifelong ADHD. Longitudinal cohort research and repeat clinical assessments address different questions from one-time symptom surveys.
Later-life measurement is particularly challenging. Childhood records may be unavailable, informants may no longer be accessible, and cognitive changes associated with aging can resemble some inattentive symptoms. A low prevalence in older age brackets may reflect true changes and incomplete recognition simultaneously. The narrower clinical question is addressed in ADHD in Older Adults: Diagnosis, Aging, and Differential Assessment, while the lifespan trajectory is examined in Does ADHD Go Away? Persistence and Change Across the Lifespan.
Sex Differences: Boys, Girls, Men, and Women
What the prevalence literature demonstrates
Most childhood epidemiologic syntheses identify higher rates among boys than girls. In the Ayano and colleagues umbrella review, pooled estimates were approximately 10% for boys and 5% for girls. The 2024 U.S. diagnosed-prevalence study found a narrower relative gap, with 14.5% of boys and 8.8% of girls having a current diagnosis. The size of the gap depends on age, case definition, whether participants were sampled from the general community or from clinics, and whether ADHD was assessed by interviewing, symptom ratings, or recorded clinical recognition. Ayano et al., 2023; HRSA, 2026.
Sex differences in diagnosed prevalence cannot be interpreted solely as direct measures of innate susceptibility. Referral may be influenced by visible classroom disruption, presentation of inattentive symptoms, teacher and parent expectations, compensatory strategies, access to services, and the threshold at which difficulties become concerning. It is possible for a real group difference in prevalence and a diagnostic-recognition gap to coexist. The observed male-to-female ratio is therefore an aggregate result of biological, developmental, social, and measurement pathways. NICE NG87; Faraone et al., 2021.
Under-recognition of ADHD in girls and women
NICE specifically advises that ADHD may be under-recognized in girls and women; they may be referred less frequently and may receive an alternative diagnostic explanation. This recommendation is a clinical recognition safeguard, not a declaration that every sex difference in prevalence results from missed cases. Population-wide estimates of the number of undiagnosed girls require independent ascertainment of clinical ADHD among diagnosed and undiagnosed participants. Referral-based studies alone cannot measure that denominator. NICE NG87, recognition.
Inattention, emotional difficulties, social effort, and complex compensatory behaviors can affect who is noticed. Hyperactivity may be expressed less as overt running or climbing in older groups and more as restlessness. The evidence supports attentive assessment across symptom presentations, but there is no clinically valid single female ADHD profile applicable to everyone. Diagnostic interviews should examine the full developmental pattern, several settings, impairment, and alternative explanations. For clinical presentation and support across the lifespan, see ADHD in Women and Girls: Recognition, Masking, and Clinical Care.
Adult sex differences are smaller or method-dependent
The 2023 U.S. adult survey described the composition of adults with current diagnoses rather than providing a universal sex-stratified clinical-prevalence rule. Adults diagnosed later can include a substantial proportion of women whose difficulties were unrecognized in childhood. A 2025 meta-analysis of clinical-setting ADHD prevalence found a clear sex difference in pediatric clinic samples but did not establish a statistically clear sex difference in its adult clinical samples. Because clinic samples are selected populations, their sex balance should not be used as a direct general-population prevalence estimate. CDC MMWR, 2024; clinical-settings meta-analysis, 2025.
Biological sex, gendered recognition, and the limits of survey categories
Many studies record binary sex categories, others use gender categories, and still others use parent-reported boy or girl status without clarifying biological or identity measures. Different conceptual variables should not be silently merged. Research on transgender and gender-diverse populations is affected by small samples, varying definitions, selected referral groups, and confidentiality considerations. Good epidemiologic reporting names the exact variable that was measured, states sample restrictions, and avoids imputing a population rate where data are too sparse for reliable estimation.
Geographic Differences and Health-System Context
ADHD has been documented across world regions. A comparison of countries requires attention to the health system and the research instrument before attributing differences to underlying neurobiology or culture. The prevalence reported in a country with universal child assessments is not directly comparable to the proportion of people receiving specialist diagnoses in a system with restricted services. Insurance coverage, wait times, school referral policies, professional training, socioeconomic barriers, stigma, and language-appropriate assessment affect measured recognition.
Different instruments may also translate poorly across language and educational contexts. A checklist item describing interrupting others may be interpreted through local norms; a school-based impairment criterion assumes comparable educational demands. Many surveys have limited coverage in low-income settings, and pooled high-income evidence may dominate numerical weights. Regional contrasts should be evaluated within studies applying a comparable case definition and rigorous sampling rather than inferred from two unrelated national headlines. Polanczyk et al., 2014; Martin et al., 2025.
Health disparities and unequal opportunities for recognition
U.S. survey estimates differ by race and ethnicity, but those differences are shaped by heterogeneous populations and care pathways. Diagnostic access, insurance, language, clinician expectations, experiences of discrimination, and family resources may influence whether difficulties result in a recorded diagnosis. A higher administrative rate does not automatically mean greater underlying susceptibility; a lower recorded rate does not show that children experience fewer problems. Epidemiology should separate estimates of clinical need from estimates of who reaches assessment and treatment. CDC child ADHD data.
A particularly important denominator issue is the difference between all residents and people enrolled in a given insurance plan, clinic, school, or digital-health system. Commercial insurance analyses can miss people with public insurance or no insurance; publicly funded systems may represent a distinct mix of service needs. Electronic health records often include repeated encounters from people who use services frequently and almost no information about individuals outside that health system. Appropriate sampling weights, linkage checks, and sensitivity analyses are essential for equitable interpretation.
Have ADHD Rates Actually Increased?
Diagnostic trends and biological prevalence follow different clocks
Over the past decades, many jurisdictions have recorded more ADHD diagnoses, referrals, and prescriptions, especially among previously overlooked adults. A rise in recorded diagnoses may reflect improved recognition, changes in diagnostic practice, evolving health-system coding, broadened access, changing help-seeking behavior, or the accumulation of historical cases. It can also coexist with a change in actual disorder prevalence. Establishing the latter requires representative studies that apply sufficiently comparable diagnostic criteria over time. A single clinic's waiting list cannot decide the issue.
In 2014, Polanczyk and colleagues found no evidence of a consistent rise in child and adolescent ADHD prevalence across the three decades examined after considering study methods. A 2025 systematic review by Martin and colleagues assessed reports from 2020 onward, examining 40 studies across 17 countries and one multinational study spanning 42 countries. It found no conclusive increase in underlying prevalence, although incidence estimates varied around the COVID-19 period. Only four included studies were at low risk of bias, and substantial data gaps prevent a precise worldwide trend estimate. This supports a measured conclusion: the best evidence does not establish a large recent global increase, while changing diagnosis and service demand remain important and real. Polanczyk et al., 2014; Martin et al., 2025.
The pandemic and changes in ascertainment
Pandemic disruptions affected schooling, health services, remote evaluations, social routines, and demands placed on families. These conditions could influence both symptom expression and the likelihood of an assessment being sought or completed. Studies using first diagnosis dates may show a temporary fall during disrupted access followed by catch-up activity. Such a pattern is different from demonstrating a biological increase in neurodevelopmental susceptibility. The Martin review identified variation in reported incidence but insufficient high-quality evidence to claim a clear prevalence increase after 2020. Martin et al., 2025.
Diagnostic awareness and social media
Public conversation, educational materials, and online accounts can prompt people to recognize longstanding difficulties and seek an appropriate assessment. They can also circulate vague checklists whose items overlap with common experiences of fatigue, stress, and distractibility. Awareness alone does not prove underdiagnosis or overdiagnosis in a population. The relevant outcome is whether people who need clinical evaluation receive one that is thorough, equitable, developmentally informed, and attentive to impairment and alternative explanations. Search trends and self-identification rates are indicators of attention and perceived need, not independently verified diagnostic prevalence.
How Researchers Estimate ADHD: A Methodological Guide
Representative probability surveys
Probability-based household surveys attempt to sample the population rather than people already receiving treatment. They can collect symptom information, diagnostic histories, demographic variables, and indicators of daily functioning, with weights that reflect selection probability and nonresponse. Advantages include broad coverage and clear denominators. Limitations include dependence on respondent memory, underrepresentation of difficult-to-reach households, and sometimes a lack of clinician verification. A parent-reported diagnosis measure is a strong indicator of recognized ADHD when the question is well defined; it is not equivalent to a blinded diagnostic reappraisal.
Structured diagnostic interviews
Structured or semistructured interviews use standardized questions covering symptoms and impairment. Their quality depends on developmentally appropriate criteria, the interviewer's training, the ability to establish childhood onset in adults, and the collection of collateral information when possible. Standardization improves comparability but cannot eliminate disagreement about impairment thresholds or culturally specific behaviors. In child studies, separate parent and teacher reports often disagree because each observes a different setting; epidemiologic protocols need predefined rules for combining them.
Rating scales, screening, and population screening thresholds
An ADHD symptom rating scale quantifies reports of behaviors. A screening cutoff identifies people who might benefit from further evaluation. A case definition derived only from reaching that cutoff often captures both true ADHD and people experiencing similar difficulties for other reasons. Positive predictive value depends on the condition's prevalence in the sampled population as well as the scale's sensitivity and specificity. A cutoff validated in referred patients may work differently in community samples. Clinical diagnosis requires a broad developmental and psychosocial assessment, not a screening score alone. NICE NG87; ADHD Screening Tests: ASRS, Rating Scales, and Their Limits.
Medical records, insurance claims, and diagnostic codes
Administrative systems allow researchers to describe large numbers of recognized cases, trends in health contacts, prescribing, and differences between service regions. They can also miss people who are never evaluated, lack insurance, or receive care outside the system. A coded ADHD diagnosis can vary in specificity and sometimes be copied forward between encounters. When comparing annual rates, investigators should state whether they count people with any historical code, active recent encounters, two independently recorded codes, or a new code within the year. Algorithms may gain specificity at the cost of sensitivity; a rising coded rate may also reflect changes in coding behavior.
Meta-analysis and evidence quality
A pooled estimate is produced by combining studies with a declared statistical model. When the included studies use different methods and populations, heterogeneity becomes an interpretive fact rather than a nuisance to be averaged away. Confidence intervals describe uncertainty under modeling assumptions; they do not measure every source of bias, and narrow intervals can coexist with serious selection errors. Umbrella reviews may double-count primary data if overlapping reviews are treated as independent observations. Evidence appraisal should consider sampling design, case definition, participation rates, instruments, impairment rules, geography, study period, and risk of bias before emphasizing the pooled number.
Age, School Context, and Birth Cohorts
ADHD symptoms are judged relative to developmental level. Young children naturally vary widely in activity and behavioral control; adolescence and adulthood introduce new demands for sustained planning and independence. Screening instruments calibrated for a particular age should not be transferred uncritically to another. In school studies, relative age within a grade can affect teacher comparisons and referral patterns, so researchers must avoid mistaking educational placement for an individual neurodevelopmental cause.
Cross-sectional studies comparing people aged 20, 40, and 70 cannot separate the effects of aging from the effects of belonging to generations that experienced different diagnostic systems. Longitudinal designs following the same individuals improve understanding of persistence but must manage participant loss, changing instruments, and shifts in contextual demands. The epidemiologic unit remains a person meeting a defined case criterion at a defined time, not a static identity inferred from one childhood measurement.
Co-occurring Conditions and Differential Diagnostic Boundaries
ADHD frequently co-occurs with learning disorders, autism, anxiety or mood disorders, sleep problems, and other conditions. The presence of a co-occurring condition can increase likelihood of contact with services, thereby raising the proportion of ADHD in clinical samples. Overlapping symptoms may also produce false positives when assessments do not establish developmental onset and distinct functional impairment. Population research should state whether comorbidity was permitted, separately assessed, or used as an exclusion criterion. Excluding all co-occurring disorders can remove many genuine ADHD cases and produce unrepresentative prevalence figures. Faraone et al., 2021; NICE NG87.
Anxiety-related distractibility, sleep deprivation, depression-associated poor concentration, substance-related symptoms, and effects of medications can mimic elements of ADHD. The longitudinal pattern, number of settings affected, degree of impairment, collateral history, and temporal relationship to another condition determine the clinical interpretation. General distraction and executive-function challenges extend beyond ADHD. For ADHD-specific differential diagnosis, see ADHD Misdiagnosis: Common Lookalikes and Clinical Pitfalls. The separate cross-cluster comparison Anxiety and ADHD: Comorbidity, Restlessness, Attention, and Differential Diagnosis develops the anxiety distinction.
Why Epidemiology Matters for Policy and Everyday Life
Accurate estimates guide the distribution of pediatric assessment capacity, adult diagnostic services, school support, workplace accommodations, trained clinicians, and medication monitoring. A government planning specialist clinics should not simply multiply an adult symptom-screen prevalence by population size and call the result the number of confirmed clinical cases. Conversely, relying only on currently treated cases can conceal unmet need. Planning requires separate estimates of possible clinical need, previously diagnosed individuals, people requesting evaluation, individuals receiving treatment, and groups facing barriers to access.
Prevalence also matters when interpreting health-outcome associations. People with a recorded ADHD diagnosis may differ from undiagnosed people with similar symptoms in severity, comorbidity, education, income, and healthcare contact. Estimates of school performance, injury, occupational outcomes, or mental-health risk can be confounded by these differences. Well-designed studies adjust for plausible confounders and acknowledge uncertainty rather than treating every association as evidence of causation.
From an individual's perspective, prevalence establishes that ADHD is a substantial and well-studied population health concern. It cannot diagnose a person, predict whether symptoms will persist, or determine a treatment plan. A thorough assessment incorporates life history, context, current impairment, and co-occurring problems. People who recognize difficulties can seek evaluation while maintaining an open investigation of possible causes. NICE NG87.
Evidence Status and Persistent Research Questions
The existence of ADHD in diverse populations and its substantial frequency among children and adults are established by multiple research traditions. Higher childhood diagnosed prevalence among boys is consistently observed, while the exact size of that difference depends on setting and measurement. Substantial adult recognition, including diagnosis first made in adulthood, is supported by national surveillance and clinical evidence. Precise global prevalence estimates remain contingent on criteria and study composition. Ayano et al., 2023; Song et al., 2021; CDC MMWR, 2024.
Evidence about the worldwide rate of change after 2020 is limited by inconsistent methods and sparse low-risk-of-bias studies. The 2025 systematic review did not find a convincing global increase in prevalence and noted fluctuations in incidence; it also described major missing information. Quantifying underdiagnosis among girls, racial and ethnic minorities, people with limited healthcare access, and older adults requires surveys that assess symptoms and clinical criteria irrespective of whether participants have previously received a diagnosis. Martin et al., 2025.
An improved next generation of ADHD epidemiology would combine representative community recruitment, comparable structured diagnostic protocols, validated translated instruments, multiple informants when appropriate, functional impairment measures, high-quality administrative linkage, and repeated observations across ages. Transparent sex and gender definitions, stratified uncertainty intervals, and cross-national collaboration would clarify which differences reflect incidence, recognition, or measurement. Such research would support more equitable service planning and stronger causal inference.
Frequently Asked Questions About ADHD Prevalence
What percentage of children worldwide have ADHD?
An umbrella review of global childhood and adolescent meta-analyses estimated 8.0%, with a 95% confidence interval of 6.0%–10.0%. Other syntheses have estimated rates around 5%–6% using different inclusion criteria and methodologies. A reliable answer gives the source, population, diagnostic definition, and study period with the percentage. Ayano et al., 2023; Faraone et al., 2021.
How common is diagnosed ADHD among U.S. children?
In the 2024 National Survey of Children's Health, 11.7% of children ages 3–17 had parent-reported current ADHD, representing approximately 7.1 million children. The data brief was published in July 2026. This is diagnosed prevalence from a survey, not a direct clinical reassessment of all children. HRSA, 2026.
How common is ADHD in adults?
One global synthesis estimated 2.58% persistent adult ADHD with childhood onset and 6.76% symptomatic ADHD under a broader definition. A distinct U.S. survey estimated 6.0% of adults had a current reported diagnosis in late 2023. Definitions and sources account for an important share of the difference. Song et al., 2021; CDC MMWR, 2024.
Is ADHD more common in boys than girls?
Childhood population syntheses and U.S. diagnosed-prevalence surveys consistently report higher observed rates in boys. The global umbrella review reported approximately 10% for boys versus 5% for girls; the 2024 U.S. diagnosed-prevalence rates were 14.5% for boys and 8.8% for girls. Referral differences and under-recognition of girls also matter, so those proportions should be interpreted with their case definitions and ascertainment methods. Ayano et al., 2023; HRSA, 2026; NICE NG87.
Have ADHD diagnoses increased because ADHD itself has become more common?
Recorded diagnoses and demand for assessment have increased in some settings. The evidence does not establish that the underlying global prevalence of ADHD has risen to the same degree. A systematic review published in 2025 found no conclusive increase in prevalence after 2020, with major limitations in available studies. Martin et al., 2025.
Can a screening quiz determine population ADHD prevalence?
A symptom checklist estimates the proportion crossing a score threshold. Without an appropriately validated diagnostic protocol, age-specific norms, and information about impairment and onset, that proportion cannot be assumed to equal the prevalence of clinically diagnosed ADHD. Screening can identify people who may benefit from further assessment, while clinical diagnosis is a separate process. NICE NG87.
Related Articles
Cluster ADHD and Executive Function — The central scientific chapter on the disorder, mechanisms, clinical assessment, treatment, and everyday functioning.
ADHD: Symptoms, Causes, Diagnosis, and Treatment — A comprehensive account of the clinical condition whose population distribution is studied here.
ADHD in Adults: Symptoms, Daily Function, and Support — Adult symptom presentations and clinical context behind adult prevalence measures.
ADHD in Women and Girls: Recognition, Masking, and Clinical Care — Sex- and gender-related pathways of recognition and care.
Does ADHD Go Away? Persistence and Change Across the Lifespan — Longitudinal course and changing definitions of remission.
ADHD Screening Tests: ASRS, Rating Scales, and Their Limits — Why screening prevalence and diagnostic prevalence differ.
References
Ayano, G., Demelash, S., Gizachew, Y., Tsegay, L., and Alati, R. (2023). The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses. Journal of Affective Disorders, 339, 860–866. https://doi.org/10.1016/j.jad.2023.07.071.
Bitsko, R. H., et al. (2024). ADHD prevalence among U.S. children and adolescents in 2022: Diagnosis, severity, co-occurring disorders, and treatment. Journal of Clinical Child and Adolescent Psychology. https://pubmed.ncbi.nlm.nih.gov/38778436/.
Centers for Disease Control and Prevention. (2024). Attention-deficit/hyperactivity disorder diagnosis, treatment, and telehealth use in adults—National Center for Health Statistics Rapid Surveys System, United States, October–November 2023. Morbidity and Mortality Weekly Report, 73, 890–895. https://www.cdc.gov/mmwr/volumes/73/wr/mm7340a1.htm.
Centers for Disease Control and Prevention. (2026). Data on ADHD in children. https://www.cdc.gov/adhd/data/.
Faraone, S. V., et al. (2021). The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 128, 789–818. https://doi.org/10.1016/j.neubiorev.2021.01.022.
Health Resources and Services Administration. (2026). Attention-deficit/hyperactivity disorder (ADHD) prevalence and health care access, 2024. National Survey of Children's Health Data Briefs. https://www.ncbi.nlm.nih.gov/books/NBK624161/.
Martin, A. F., Rubin, G. J., Rogers, M. B., Wessely, S., Greenberg, N., Hall, C. E., et al. (2025). The changing prevalence of ADHD? A systematic review. Journal of Affective Disorders, 388, 119427. https://doi.org/10.1016/j.jad.2025.119427.
National Institute for Health and Care Excellence. (2018, updated 2019). Attention deficit hyperactivity disorder: Diagnosis and management (NG87). https://www.nice.org.uk/guidance/ng87/chapter/recommendations.
National Survey of Children's Health Data Resource Center. (2024). National results for indicator 2.7: Current ADD or ADHD, children aged 3–17. https://www.nschdata.org/browse/survey/results?q=12384&r=1.
Polanczyk, G. V., Willcutt, E. G., Salum, G. A., Kieling, C., and Rohde, L. A. (2014). ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis. International Journal of Epidemiology, 43, 434–442. https://doi.org/10.1093/ije/dyt261.
Salari, N., Ghasemi, H., Abdoli, N., et al. (2023). The global prevalence of ADHD in children and adolescents: A systematic review and meta-analysis. Italian Journal of Pediatrics, 49, 48. https://doi.org/10.1186/s13052-023-01456-1.
Song, P., Zha, M., Yang, Q., Zhang, Y., Li, X., and Rudan, I. (2021). The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. Journal of Global Health, 11, 04009. https://pubmed.ncbi.nlm.nih.gov/33692893/.
Systematic review of ADHD in clinical populations. (2025). Prevalence of attention deficit hyperactivity disorder/hyperkinetic disorder of pediatric and adult populations in clinical settings: A systematic review, meta-analysis and meta-regression. Molecular Psychiatry. https://pubmed.ncbi.nlm.nih.gov/40877470/.